Question 1
(20 marks)
CUBANGO PHARMACEUTICALS LTD
Cubango Pharmaceuticals Ltd ("Cubango") is a large, NSX-listed Namibian pharmaceutical
company which develops, manufactures and distributes a diverse array of medicines locally.
It has been doing this for many years.
Cubango is currently preparing its financial statements for its year ended 31 October 2024,
which are prepared in accordance with IFRS.
1. Debentures
On 1 November 2022, Cubango purchased 50 000 debentures for their fair value of N$ 5 per
debenture. It incurred transaction costs on 1 November 2022 of N$ 5 000 when purchasing
the debentures. Cubango is entitled to a 6% coupon on 31 October each year until 31
October 2027 when the debentures will be redeemed at N$ 350 000. The debentures are
held as a portfolio with the objective to collect contractual cash flows.
At the issue date, a fair rate of interest/ the effective interest rate is 11.7731% p.a.
The debentures were assessed to have a low credit risk. Thus, the loss allowance expected
were estimated as follows:
• 01 November 2023: N$ 15 000
• 31 October 2024: N$ 20 000
2. Investment in Shares
Cubango purchased 1 000 shares in Family Limited on 01 January 2024, each share cost
N$ 260. Family Limited had retaining earning of N$ 900 000 on 01 July 2023. The company
has profit after tax of N$ 350 000 for the 30 June 2024 financial year end. On 30 June 2024
Family Limited declared dividends of N$20 per share.
Required:
a) Prepare the journal entries to account for the debentures in Cubango's accounting
records for the years ended 31 October 2023 and 31 October 2024. Journal narrations
are required.
(15)
b) Prepare an extract of the statement of changes in equity for Family Limited for the year
ended 30 June 2024 to account for Investment in shares.
(5)
QUESTION 2
(25 MARKS)
Jay Ltd is a television manufacturing company. The company's year-end is 31 December
2023. At the beginning of the financial year ended 31 December 2023 Jay Ltd started selling
all its televisions with a refund policy. If the customer is not satisfied, the television may be
returned for a full refund. Sales for the year ended 31 December amounted to N$1 500 000.
The following came to your attention before the financial statements were authorised for
issue on 16 February 204
1